Biomedical subjects
Publications and source records attributed to M Moriyama.
Explore the source record for details and available documents.
To study the clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer, we measured serum CA 125 levels in 197 patients with gynecological diseases, 274 normal, pregnant and postpartum women, 14 patients with abnormal pregnancy, 82 healthy women with a normal ovulatory menstrual cycle and 107 healthy non-pregnant subjects, using RIA kits. A level below 34 U/ml was considered the normal CA 125 range. The positive ratio of serum CA 125 in patients with malignant ovarian tumor was 81.3 per cent, and in those with serous cystadenocarcinoma the rate was 100 per cent. On the other hand, only one patient with benign ovarian tumor had a positive CA 125 value. Therefore, we suggest that CA 125 is useful for differentiation between benign ovarian tumor and ovarian cancer. However, because the positive ratio of CA 125 level is high in patients with recurrences of uterine cervical adenocarcinoma, those with tubal cancer, endometriosis, early pregnancy, abnormal pregnancy plus intrauterine fetal death and menstruating women, such situations must be given due attention when CA 125 is used as a tumor marker of ovarian cancer.
Chromosome analysis was performed on peripheral blood lymphocytes of a patient with rhabdomyosarcoma of the urinary bladder. It showed a reciprocal t(2;5) translocation with the breakpoints at 2q37.3 and 5q31.3. This is the first report of such an anomaly in the peripheral lymphocytes of a patient with rhabdomyosarcoma of the urinary bladder.
The effects of mouse interferon-alpha/beta (MuIFN) or poly(I):poly(C) injection on the lymphocytes in the blood, thymus, and spleen of C3H/HeN mice were examined. A single injection of MuIFN (2 X 10(6) to 2 X 10(7) IU/kg of MuIFN) or poly(I):poly(C) (0.12-1.2 mg/kg) caused a significant lymphocytopenia without any evidence of direct cytotoxic effects on lymphocytes in the blood or lymphoid organs, a significant decrease in the number of T cells both in the thymus and spleen along with a significant increase in the number of non-T cells in the splenic white pulp, and a differential decrease in the number of blood T-cell subsets ("suppressor/cytotoxic" subset was decreased continuously whereas "helper" subset only transiently). The differential effect on T-cell subsets could explain the complicated effects of IFN on the cell-mediated immune response.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Forty five patients with previously untreated prostatic cancer were given chlormadinone acetate (CMA) at a dose of 100 mg/day (mean 12.6 months), and 42 of them were evaluated for effectiveness. Overall response evaluation revealed 19 complete responses (45.2%), 14 partial responses (33.3%), 4 minor responses (9.5%), and 5 were unresponsive (11.9%). Consequently CMA was judged to be effective in 33 patients (78.6%, complete and partial responses). Response rate was 100.0% for stage A, 88.9% for stage B, 77.8% for stage C, and 57.1% for stage D. The response rate for stage D was relatively high, possibly because the time of judgement of effectiveness was a little too early. As side effects, elevated triglyceride level, impaired liver function and impotence were noted in one patient each. All of them were slight. The testosterone level in both castrated and non-castrated patients were not higher than that in women, and no significant difference in the level was noted between the groups. Nevertheless, the clinical usefulness of castration is not denied. CMA is considered useful as an endocrine therapeutic drug, though its effect on the disease at stage D was insufficient. The administration method, such as sequential treatment and combination treatment of CMA and estrogen preparations, is a future subject.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
We studied the effect of the centralized cervical cytological screening program in Shimane prefecture and obtained the following results. After the centralized screening system was introduced, the rate detection of dysplasia almost doubled. The detection rates for carcinoma in situ and invasive carcinoma of the uterine cervix increased from 0.042% to 0.047% and from 0.042% to 0.065%, respectively. The cases with Pap. class III, IV, and V decreased to a third on the centralized cytologic screening system. The false negative rates for carcinoma in situ and invasive carcinoma decreased from 20.0% to 17.9% and from 16.0% to 7.4%, respectively. We concluded that the accuracy of the cytological diagnosis was improved by the establishment of the centralized system.